Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. (abst – 2010) http/www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=316
Chronic Δâ¹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3051379/pdf/bph0162-1060.pdf
Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3285765/pdf/213_2011_Article_2479.pdf
Tolerance to chronic delta-9-tetrahydrocannabinol (Δâ¹-THC) in rhesus macaques infected with simian immunodeficiency virus. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3140653/
Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the betalactam antibiotic, ceftriaxone, in mice. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21536061/abstract/Role_of_GLT_1_transporter_activation_in_prevention _of_cannabinoid_tolerance_by_the_beta_lactam_antib iotic_ceftriaxone_in_mice_
The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/20701826/abstract/The_schizophrenia_susceptibility_gene_neuregulin_1 _modulates_tolerance_to_the_effects_of_cannabinoid s_
Brain regional differences in CB1 receptor adaptation and regulation of transcription. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3772765/
Tolerance to Effects of High-Dose Oral {Delta}9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3584989/
Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the β-lactam antibiotic, ceftriaxone, in mice. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/21536061
Tolerance and cross-tolerance among high-efficacy synthetic cannabinoids JWH-018 and JWH-073 and low-efficacy phytocannabinoid 9-THC (abst – 2013) http/www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/1097.1?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/22878432
Prolonged monoacylglycerol lipase blockade causes equivalent CB1-receptor mediated adaptations in FAAH wild type and knockout mice. (full – 2014) http/jpet.aspetjournals.org/content/early/2014/05/21/jpet.114.212753.long
Mutation of Putative GRK Phosphorylation Sites in the Cannabinoid Receptor 1 (CB1R) Confers Resistance to Cannabinoid Tolerance and Hypersensitivity to Cannabinoids in Mice. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24719095
Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1-Dependent Withdrawal. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24853387
A new method of cannabis ingestion: The dangers of dabs? (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24930049
Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α and WIN55,212-2 at the supraspinal level in mice. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/25010019
Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/25131716
Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice (abst – 2015)http://www.sciencedirect.com/science...76871615000423
Medical pot doesn’t lead to impaired driving (news – 2015) http://www.abqjournal.com/524770/opinion/medical-pot-doesnt-lead-to-impaired-driving.html ;
Chronic Δâ¹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3051379/pdf/bph0162-1060.pdf
Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3285765/pdf/213_2011_Article_2479.pdf
Tolerance to chronic delta-9-tetrahydrocannabinol (Δâ¹-THC) in rhesus macaques infected with simian immunodeficiency virus. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3140653/
Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the betalactam antibiotic, ceftriaxone, in mice. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21536061/abstract/Role_of_GLT_1_transporter_activation_in_prevention _of_cannabinoid_tolerance_by_the_beta_lactam_antib iotic_ceftriaxone_in_mice_
The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/20701826/abstract/The_schizophrenia_susceptibility_gene_neuregulin_1 _modulates_tolerance_to_the_effects_of_cannabinoid s_
Brain regional differences in CB1 receptor adaptation and regulation of transcription. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3772765/
Tolerance to Effects of High-Dose Oral {Delta}9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3584989/
Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the β-lactam antibiotic, ceftriaxone, in mice. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/21536061
Tolerance and cross-tolerance among high-efficacy synthetic cannabinoids JWH-018 and JWH-073 and low-efficacy phytocannabinoid 9-THC (abst – 2013) http/www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/1097.1?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/22878432
Prolonged monoacylglycerol lipase blockade causes equivalent CB1-receptor mediated adaptations in FAAH wild type and knockout mice. (full – 2014) http/jpet.aspetjournals.org/content/early/2014/05/21/jpet.114.212753.long
Mutation of Putative GRK Phosphorylation Sites in the Cannabinoid Receptor 1 (CB1R) Confers Resistance to Cannabinoid Tolerance and Hypersensitivity to Cannabinoids in Mice. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24719095
Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1-Dependent Withdrawal. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24853387
A new method of cannabis ingestion: The dangers of dabs? (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24930049
Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α and WIN55,212-2 at the supraspinal level in mice. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/25010019
Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/25131716
Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice (abst – 2015)http://www.sciencedirect.com/science...76871615000423
Medical pot doesn’t lead to impaired driving (news – 2015) http://www.abqjournal.com/524770/opinion/medical-pot-doesnt-lead-to-impaired-driving.html ;